Targeting fibrosis: Mechanisms and clinical trials

M Zhao, L Wang, M Wang, S Zhou, Y Lu… - Signal transduction and …, 2022 - nature.com
Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Idiopathic pulmonary fibrosis

DJ Lederer, FJ Martinez - New England Journal of Medicine, 2018 - Mass Medical Soc
Idiopathic Pulmonary Fibrosis | NEJM Skip to main content NEJM Group Follow Us Facebook
Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge …

Idiopathic pulmonary fibrosis: pathogenesis and management

G Sgalla, B Iovene, M Calvello, M Ori, F Varone… - Respiratory …, 2018 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat

TM Maher, ME Strek - Respiratory research, 2019 - Springer
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Idiopathic pulmonary fibrosis (IPF): an overview

SL Barratt, A Creamer, C Hayton… - Journal of clinical …, 2018 - mdpi.com
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic,
progressive scarring of the lungs and the pathological hallmark of usual interstitial …

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

A Guenther, E Krauss, S Tello, J Wagner, B Paul… - Respiratory …, 2018 - Springer
Background Since 2009, IPF patients across Europe are recruited into the eurIPFreg,
providing epidemiological data and biomaterials for translational research. Methods The …

Nintedanib: a review in fibrotic interstitial lung diseases

YN Lamb - Drugs, 2021 - Springer
Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological
processes, indicating the potential for common approaches to treatment. Nintedanib …

Defining the activated fibroblast population in lung fibrosis using single-cell sequencing

R Peyser, S MacDonnell, Y Gao, L Cheng… - American journal of …, 2019 - atsjournals.org
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disorder driven by
unrelenting extracellular matrix deposition. Fibroblasts are recognized as the central …

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis

BF Collins, G Raghu - European Respiratory Review, 2019 - Eur Respiratory Soc
Two antifibrotic medications (nintedanib and pirfenidone) were recommended
(conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the …

[HTML][HTML] Acute exacerbations of progressive-fibrosing interstitial lung diseases

M Kolb, B Bondue, A Pesci, Y Miyazaki… - European …, 2018 - Eur Respiratory Soc
Acute exacerbation of interstitial lung disease (ILD) is associated with a poor prognosis and
high mortality. Numerous studies have documented acute exacerbation in idiopathic …